-
Maternal Serum Placental Growth Factor (PlGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014;36:106-16.. pdf -
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues.
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J.
FASEB J 2002;16:1271-3. -
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Spencer K, Nicolaides KH.
Prenat Diagn 2002;22:877-9. -
Second-trimester uterine artery Doppler screening in unselected populations: a review.
Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;12:78-88. -
Increased fetal nuchal translucency at 11-14 weeks.
Nicolaides KH, Heath V, Cicero S.
Prenat Diagn 2002;22:308-15. -
One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation.
Nicolaides KH, Bindra R, Heath V, Cicero S.
J Matern Fetal Neonatal Med 2002;12:9-18. -
Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening.
Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:443-8. -
Fetal nasal bone length in chromosomally normal and abnormal fetuses at 11-14 weeks of gestation.
Cicero S, Bindra R, Rembouskos G, Tripsanas C, Nicolaides KH.
J Matern Fetal Neonatal Med 2002;11:400-2. -
Screening for chromosomal defects by fetal nuchal translucency at 11 to 14 weeks.
Bindra R, Heath V, Nicolaides KH.
Clin Obstet Gynecol 2002;45:661-70.